AGM-290

AGM-290 is a preclinical peptide-based antibiotic candidate being developed by Anygen. It is specifically designed to combat infections caused by multidrug-resistant (MDR) bacteria, often referred to as "super bacteria." As an antimicrobial peptide, AGM-290 is engineered to overcome existing resistance mechanisms by directly targeting and disrupting the integrity of bacterial cell membranes. This mode of action leads to rapid cell lysis and death, making it more difficult for bacteria to develop resistance compared to traditional antibiotics. The candidate is part of Anygen's research and development pipeline focused on addressing the global threat of antibiotic resistance and providing new therapeutic options for severe bacterial infections.